Sanofi shares fall 6% after double setback for MS drug tolebrutinib
The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.
Therapy Area
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
ASH 2025: J&J’s Tecvayli + Darzalex set to redefine early relapsed MM
GRI Bio’s tazarotene achieves Phase IIa IPF success
Roche posts second Phase III win for oral SERD
New HBV vaccine guidance likely to increase infection among newborns
ASH 2025: Arcellx and Gilead’s Anito-cel challenges CAR-T market in R/R MM
BMS delays Alzheimer’s readout for Cobenfy over “site irregularities”
